Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 14/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476938 | 0.80 | KCNH2 (0.41) | CCR4GRNSORT1MEN1OPRM1 | |
| SCHEMBL249047 | 0.79 | CCR1 (0.40) | CCR1TERTALDH1A1 | |
| SCHEMBL22335908 | 0.78 | KCNH2 (0.42) | CCR1TERTNPSR1 | |
| SCHEMBL12664449 | 0.78 | KCNH2 (0.45) | CCR1TERTALDH1A1NPSR1 | |
| SCHEMBL21357417 | 0.77 | TERT (0.34) | CCR1TERTALDH1A1 | |
| SCHEMBL29368972 | 0.77 | TERT (0.34) | CCR1TERTALDH1A1 | |
| SCHEMBL7095200 | 0.76 | KCNH2 (0.46) | CCR1TERTALDH1A1NPSR1 | |
| SCHEMBL947122 | 0.75 | BACE1 (0.36) | CCR1TERT | |
| SCHEMBL22354808 | 0.75 | CCR1 (0.40) | CCR1TERTALDH1A1 | |
| SCHEMBL6984612 | 0.75 | CCR1 (0.40) | CCR1TERTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | CCR1 2351/4885TERT 3725/4885ALDH1A1 101/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | CCR1 420/4885TERT 4323/4885ALDH1A1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.